



Corrigendum

Corrigendum to “Targeted Prostate Cancer Screening in *BRCA1* and *BRCA2* Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study” [Eur Urol 2014;66:489–99]

Elizabeth K. Bancroft ^{a,b}, Rosalind A. Eeles ^{b,a,*},
on behalf of the authors

^a Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK; ^b Oncogenetics Team, Institute of Cancer Research, London, UK

The diagram listed as Figure 2 inadvertently contained four typographical errors and should be replaced by the figure that is placed below. The number of *BRCA1* carriers with prostate-specific antigen ≤ 3 ng/ml was 731 (not 732), the positive predictive value of biopsy in *BRCA1* carriers was 37.5% (not 40.9%); 80.0% (not 60%) of *BRCA1* controls and 70.8% (not 68%) of *BRCA2* carriers had intermediate/high risk disease. These changes do not change the content (the data are correct in the text and the tables) or the conclusions of the paper.




Fig. 2 – Consort diagram for the first round of screening. *BRCA1* = breast cancer 1, early onset; *BRCA2* = breast cancer 2, early onset; PSA = prostate-specific antigen; PPV = positive predictive value. * Controls were men who had a negative predictive genetic test for the *BRCA* mutation in their family.

DOI of original article: <http://dx.doi.org/10.1016/j.eururo.2014.01.003>.

* Corresponding author. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton SM2 5NG, UK.

Tel. +44 208 722 4094; Fax: +44 208 722 4110.

E-mail address: ros.eeles@icr.ac.uk (R.A. Eeles).

<http://dx.doi.org/10.1016/j.eururo.2014.12.001>